Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
8.17
-0.32 (-3.77%)
At close: Mar 28, 2025, 4:00 PM
8.15
-0.02 (-0.24%)
Pre-market: Mar 31, 2025, 7:00 AM EDT

Arcus Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2016
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2016
Net Income
-283-307-26753-123
Upgrade
Depreciation & Amortization
108643
Upgrade
Asset Writedown & Restructuring Costs
20----
Upgrade
Loss (Gain) From Sale of Investments
-25-19-5-
Upgrade
Stock-Based Compensation
7673655522
Upgrade
Other Operating Activities
10101131
Upgrade
Change in Accounts Receivable
2815704-17-1
Upgrade
Change in Accounts Payable
3-18-59
Upgrade
Change in Unearned Revenue
-56-68-112-368188
Upgrade
Change in Other Net Operating Assets
47-17231412
Upgrade
Operating Cash Flow
-170-306438-256111
Upgrade
Capital Expenditures
-6-24-6-26-3
Upgrade
Investment in Securities
-78218-40422-431
Upgrade
Other Investing Activities
---3--
Upgrade
Investing Cash Flow
-84194-413-4-434
Upgrade
Long-Term Debt Issued
47----
Upgrade
Net Debt Issued (Repaid)
47----
Upgrade
Issuance of Common Stock
2373323232439
Upgrade
Repurchase of Common Stock
-7----
Upgrade
Other Financing Activities
--105-
Upgrade
Financing Cash Flow
2773333237439
Upgrade
Net Cash Flow
23-7958-23116
Upgrade
Free Cash Flow
-176-330432-282108
Upgrade
Free Cash Flow Margin
-68.22%-282.05%385.71%-73.63%138.46%
Upgrade
Free Cash Flow Per Share
-1.95-4.466.00-3.811.97
Upgrade
Cash Interest Paid
1----
Upgrade
Cash Income Tax Paid
-53--
Upgrade
Levered Free Cash Flow
-41.25-187.75617.75-644.7540.73
Upgrade
Unlevered Free Cash Flow
-38.75-186.5619-644.7540.73
Upgrade
Change in Net Working Capital
-7531-729711.5-96.23
Upgrade
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q